We form partnerships for completing clinical studies.

Our expertise lies in the discovery, preclinical and early clinical aspects of drug development. Our business strategy is to identify and advance our lead therapeutic compounds into Phase 1 clinical studies and then partner with or license the intellectual property to a pharmaceutical company to continue our compounds’ clinical development programs. We are currently in partnering discussions for clinical development of our lead compound, NDC-1308, a novel chemical entity designed to induce oligodendrocyte progenitor cells (OPCs) – the precursors of oligodendrocytes – to mature into oligodendrocytes, the cells that synthesize and maintain the myelin sheath.

We never lose sight of our ultimate goal: to develop innovative therapies for patients who need them urgently to treat devastating diseases with few therapeutic options.